Inventor · disambiguated record
He Sun
Also filed as: SUN HE
20 granted patents·8 pending applications·17 citations·filing 2011–2024
90Inventor score
Files withTASLY PHARMACEUTICAL GROUP CO11INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD9INNOVATIVE CELLULAR THERAPEUTICS CO LTD5CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE CHINESE ACAD OF SCIENCES1SUN HE1
Top patents by PatentIndex Score
28 records- 0195US9932405B2Use of chimeric antigen receptor modified cells to treat cancerINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2017·Granted Apr 3, 2018·13 cites·8 claims
- 0288US10793638B2Use of chimeric antigen receptor modified cells to treat cancerINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2018·Granted Oct 6, 2020·2 cites·15 claims
- 0382US2024218075A1Use of chimeric antigen receptor modified cells to treat cancerINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2024·Application pending·0 cites
- 0481US2025188146A1Modified Cell Expansion and Uses ThereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2024·Application pending·0 cites
- 0579US12090138B2Pharmaceutical composition containing silybin and VETASLY PHARMACEUTICAL GROUP CO·Filed 2022·Granted Sep 17, 2024·0 cites·8 claims
- 0672US12150960B2Modified cell expansion and uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Granted Nov 26, 2024·0 cites·7 claims
- 0772US2025171560A1Chimeric antigen receptor cells for treating solid tumorINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2024·Application pending·0 cites
- 0871US11932700B2Use of chimeric antigen receptor modified cells to treat cancerINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Granted Mar 19, 2024·0 cites·9 claims
- 0970US12240915B2Chimeric antigen receptor cells for treating solid tumorINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2019·Granted Mar 4, 2025·0 cites·19 claims
- 1069US11161913B2Chimeric antigen receptor cells for treating solid tumorINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2021·Granted Nov 2, 2021·0 cites·13 claims
- 1168US11981920B2Modified cell with enhanced migration capabilityINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2019·Granted May 14, 2024·0 cites·15 claims
- 1267US9072745B2Use of Salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart diseaseYAN XIJUN·Filed 2011·Granted Jul 7, 2015·2 cites·28 claims
- 1365US10307395B2Pharmaceutical composition containing silybin and L-carnitineTASLY PHARMACEUTICAL GROUP CO·Filed 2016·Granted Jun 4, 2019·0 cites·20 claims
- 1465US10307396B2Pharmaceutical composition containing silybin, VE and L-carnitineTASLY PHARMACEUTICAL GROUP CO·Filed 2016·Granted Jun 4, 2019·0 cites·20 claims
- 1562US2021161961A1Modified Cell Expressing Therapeutic Agent and Uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2021·Application pending·0 cites
- 1661US10507197B2Pharmaceutical composition containing silibininTASLY PHARMACEUTICAL GROUP CO·Filed 2016·Granted Dec 17, 2019·0 cites·20 claims
- 1760US11318112B2Pharmaceutical composition containing silybin and veTASLY PHARMACEUTICAL GROUP CO·Filed 2016·Granted May 3, 2022·0 cites·18 claims
- 1860US10376491B2Pharmaceutical composition containing silibinin and pueraria root extractTASLY PHARMACEUTICAL GROUP CO·Filed 2016·Granted Aug 13, 2019·0 cites·20 claims
- 1959US10654934B2Use of chimeric antigen receptor modified cells to treat cancerINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2018·Granted May 19, 2020·0 cites·33 claims
- 2059US2023390353A1Pharmaceutical composition for treating myocardial ischemia and preparation method thereforTASLY PHARMACEUTICAL GROUP CO·Filed 2022·Application pending·0 cites
- 2158US11788072B2Activation of APC in immunotherapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Granted Oct 17, 2023·0 cites·18 claims
- 2254US2021379149A1Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell TherapyINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2019·Application pending·0 cites
- 2350US2023201293A1Application of a traditional chinese medicine composition and formulation thereof in the preparation of medicaments for preventing and/or treating novel coronavirus pneumoniaTASLY PHARMACEUTICAL GROUP CO·Filed 2021·Application pending·0 cites
- 2447US2024042026A1Chimeric antigen receptor and use thereofCENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE CHINESE ACAD OF SCIENCES·Filed 2021·Application pending·0 cites
- 2542US11491173B2Pharmaceutical composition and application thereofTASLY PHARMACEUTICAL GROUP CO·Filed 2019·Granted Nov 8, 2022·0 cites·19 claims
- 2640US10874636B2Application of substituted cinnamamide derivatives in preparation of anti-anxiety medicationTASLY PHARMACEUTICAL GROUP CO·Filed 2017·Granted Dec 29, 2020·0 cites·9 claims
- 2737US10376490B2Pharmaceutical composition containing silybinTASLY PHARMACEUTICAL GROUP CO·Filed 2016·Granted Aug 13, 2019·0 cites·17 claims
- 2825US9205123B2Capsule of compound danshen dripping pillsSUN HE·Filed 2011·Granted Dec 8, 2015·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when He Sun files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →